1y return+67.0%S&P 500 +20.9%
3y return+47.7%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2022: $164 against $195 in the S&P 500.2
Braidwell LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CAICaris Life Sciences Inc | $147.1M | 5.6% | +3.1% |
| HNGEHinge Health Inc | $110.4M | 4.2% | −8.6% |
| GKOSGlaukos Corp | $82.7M | 3.2% | −22.5% |
| EWTXEdgewise Therapeutics Inc | $81.1M | 3.1% | −14.9% |
| SYRESpyre Therapeutics Inc | $78.1M | 3.0% | −5.7% |
| IRTCIrhythm Holdings Inc | $77.8M | 3.0% | +7.2% |
| NEONeogenomics Inc | $71.8M | 2.8% | −12.4% |
| KODKodiak Sciences Inc | $69.6M | 2.7% | −1.7% |
| XENEXenon Pharmaceuticals Inc | $68.3M | 2.6% | −15.5% |
| GLUEMonte Rosa Therapeutics Inc | $59.3M | 2.3% | −23.5% |
| DNTHDianthus Therapeutics Inc | $58.0M | 2.2% | −33.9% |
| NBIXNeurocrine Biosciences Inc | $56.7M | 2.2% | −48.4% |
| ATECAlphatec Hldgs Inc | $56.5M | 2.2% | +200.6% |
| GENBGenerate Biomedicines Inc | $55.4M | 2.1% | −8.6% |
| MRVIMaravai Lifesciences Hldgs I | $54.3M | 2.1% | −15.0% |
| KRYSKrystal Biotech Inc | $47.9M | 1.8% | −29.3% |
| HUMHumana Inc | $45.5M | 1.7% | New |
| TMOThermo Fisher Scientific Inc | $44.8M | 1.7% | −3.8% |
| KYMRKymera Therapeutics Inc | $43.4M | 1.7% | +12.0% |
| RYTMRhythm Pharmaceuticals Inc | $42.3M | 1.6% | +22.7% |
| Damora Therapeutics IncCUSIP 36322Q206 | $42.1M | 1.6% | +81.1% |
| ACADAcadia Pharmaceuticals Inc | $41.7M | 1.6% | −33.4% |
| BTSGBrightspring Health Svcs Inc | $41.6M | 1.6% | −41.3% |
| TMDXTransmedics Group Inc | $40.5M | 1.6% | +85.1% |
| MBXMbx Biosciences Inc | $39.2M | 1.5% | −52.4% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| KRYSKrystal Biotech Inc | December 31, 2022 | +369.2% | $47.9M |
| SYRESpyre Therapeutics Inc | December 31, 2023 | +312.5% | $78.1M |
| GKOSGlaukos Corp | December 31, 2022 | +220.0% | $82.7M |
| DNTHDianthus Therapeutics Inc | September 30, 2025 | +147.7% | $58.0M |
| KYMRKymera Therapeutics Inc | September 30, 2025 | +102.6% | $43.4M |
| CDNACaredx Inc | September 30, 2025 | +96.0% | $34.8M |
| CLYMClimb Bio Inc | March 31, 2026 | +90.4% | $36.5M |
| NEONeogenomics Inc | September 30, 2025 | +89.0% | $71.8M |
| BTSGBrightspring Health Svcs Inc | December 31, 2025 | +86.2% | $41.6M |
| MBXMbx Biosciences Inc | December 31, 2025 | +75.0% | $39.2M |
Sold off last quarter
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $78.9M
- Nuvalent IncCUSIP 670703107 was $71.8M
- CGONCg Oncology Inc was $66.7M
- Apogee Therapeutics IncCUSIP 03770N101 was $40.3M
- PENPenumbra Inc was $34.6M
- Soleno Therapeutics IncCUSIP 834203309 was $32.1M
- ILMNIllumina Inc was $28.3M
- BMRNBiomarin Pharmaceutical Inc was $28.1M
- Establishment Labs Hldgs IncCUSIP G31249108 was $26.3M
- FULCFulcrum Therapeutics Inc was $24.0M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +25.4% | +14.8% |
| March 31, 2026 | +0.4% | −4.6% |
| December 31, 2025 | +18.2% | +2.4% |
| September 30, 2025 | +12.3% | +7.8% |
| June 30, 2025 | +6.0% | +10.5% |
| March 31, 2025 | −14.7% | −4.6% |
| December 31, 2024 | −5.8% | +2.1% |
| September 30, 2024 | +10.5% | +5.4% |
| June 30, 2024 | −10.1% | +4.0% |
| March 31, 2024 | +7.0% | +10.0% |
| December 31, 2023 | +10.5% | +11.2% |
| September 30, 2023 | −11.5% | −3.6% |
| June 30, 2023 | +11.3% | +8.3% |
| March 31, 2023 | +0.0% | +7.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Braidwell LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1920938&type=13F-HR&dateb=&owner=include&count=40CIK 1920938
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1920938/000142050626001823/Filed August 14, 2026 · accession 0001420506-26-001823